Table 2.
Cross‐Sectional Association of Cardiac Biomarkers With Year 1 KCCQ Score <75 in Persons With CKD Without HF in the CRIC Study (N=2873)
| KCCQ score <75 Model 0 OR (99% CI) | KCCQ score <75 Model 1 aOR (99% CI) | KCCQ Score <75 Model 2 aOR (99% CI) | |
|---|---|---|---|
| GDF‐15 continuous model | 1.56 (1.39, 1.75)a | 1.60 (1.41, 1.82)a | 1.42 (1.19, 1.68)a |
| Log(GDF‐15) per 1 SD (0.58 pg/mL) increase | |||
| GDF‐15 categorical model | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| Quintile 1 (≤856 pg/mL) | |||
| Quintile 2 (857–1200 pg/mL) | 1.30 (0.86, 1.96) | 1.31 (0.86, 2.01) | 1.08 (0.67, 1.73) |
| Quintile 3 (1201–1570 pg/mL) | 2.16 (1.47, 3.19)a | 2.31 (1.54, 3.47)a | 1.65 (1.03, 2.66)a |
| Quintile 4 (1571–2220 pg/mL) | 2.66 (1.81, 3.89)a | 2.81 (1.87, 4.23)a | 1.93 (1.17, 3.18)a |
| Quintile 5 (>2220 pg/mL) | 3.29 (2.26, 4.80)a | 3.52 (2.34, 5.29)a | 2.35 (1.39, 3.97)a |
| Galectin‐3 continuous model | 1.61 (1.42, 1.83)a | 1.49 (1.31, 1.69)a | 1.28 (1.12, 1.48)a |
| Log(Galectin‐3) per 1 SD (0.50 pg/mL) increase | |||
| Galectin‐3 categorical model | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| Quintile 1 (≤9.11 pg/mL) | |||
| Quintile 2 (9.12–12.2 pg/mL) | 1.53 (1.02, 2.29)a | 1.45 (0.96, 2.18) | 1.29 (0.84, 1.99) |
| Quintile 3 (12.3–15.4 pg/mL) | 1.86 (1.26, 2.75)a | 1.64 (1.10, 2.45)a | 1.36 (0.88, 2.08) |
| Quintile 4 (15.5–20.1 pg/mL) | 2.49 (1.70, 3.65)a | 2.15 (1.46, 3.19)a | 1.63 (1.06, 2.50)a |
| Quintile 5 (>20.1 pg/mL) | 3.45 (2.37, 5.02)a | 2.76 (1.87, 4.07)a | 1.80 (1.17, 2.78)a |
| sST‐2 continuous model | 1.12 (0.99, 1.26) | 1.20 (1.05, 1.38)a | 1.12 (0.98, 1.28) |
| Log(sST‐2) per 1 SD (0.55 pg/mL) increase | |||
| sST‐2 categorical model | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| Quintile 1 (≤10.4 pg/mL) | |||
| Quintile 2 (10.5–13.4 pg/mL) | 1.17 (0.81, 1.67) | 1.25 (0.86, 1.80) | 1.09 (0.73, 1.64) |
| Quintile 3 (13.5–16.8 pg/mL) | 1.36 (0.95, 1.94) | 1.51 (1.05, 2.17)a | 1.35 (0.91, 2.01) |
| Quintile 4 (16.9–22 pg/mL) | 1.14 (0.80, 1.64) | 1.37 (0.94, 2.00) | 1.06 (0.70, 1.60) |
| Quintile 5 (> 22 pg/mL) | 1.49 (1.05, 2.12)a | 1.90 (1.31, 2.75)a | 1.51 (1.00, 2.28)a |
| hsTnT continuous model | 1.30 (1.17, 1.45)a | 1.44 (1.26, 1.63)a | 1.10 (0.93, 1.31) |
| Log(hsTnT) per 1 SD (0.77 ng/L) increase | |||
| hsTnT categorical model | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| <Lower limit of detection (<10 ng/L) | |||
| Tertile 1 (10.1–14.7 ng/L) | 1.15 (0.83, 1.59) | 1.33 (0.95, 1.87) | 1.06 (0.73, 1.55) |
| Tertile 2 (14.8–23.9 ng/L) | 1.55 (1.15, 2.10)a | 1.91 (1.37, 2.65)a | 1.20 (0.82, 1.75) |
| Tertile 3 (>23.9 ng/L) | 1.80 (1.34, 2.42)a | 2.26 (1.61, 3.16)a | 1.17 (0.77, 1.78) |
| NT‐proBNP continuous model | 1.29 (1.15, 1.46)a | 1.30 (1.14, 1.47)a | 1.03 (0.88, 1.21) |
| Log(NT‐proBNP) per 1 SD (1.60 pg/mL) increase | |||
| NT‐proBNP categorical model | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| Quintile 1 (≤30.9 pg/mL) | |||
| Quintile 2 (31–76 pg/mL) | 1.03 (0.71, 1.50) | 1.00 (0.68, 1.46) | 0.86 (0.57, 1.30) |
| Quintile 3 (76.1–158 pg/mL) | 1.26 (0.87, 1.81) | 1.26 (0.87, 1.84) | 0.95 (0.63, 1.44) |
| Quintile 4 (158.1–370 pg/mL) | 1.50 (1.05, 2.14)a | 1.50 (1.03, 2.17)a | 0.95 (0.61, 1.47) |
| Quintile 5 (>370 pg/mL) | 1.96 (1.38, 2.78)a | 1.92 (1.32, 2.79)a | 1.03 (0.65, 1.63) |
Model 0: Unadjusted; Model 1: Age, sex, race/ethnicity; Model 2: M1 + myocardial infarction, chronic obstructive pulmonary disease, atrial fibrillation, stroke, diabetes mellitus, systolic blood pressure, body mass index, current smoking, estimated glomerular filtration rate, 24 h urinary protein, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, diuretics, and beta blocker use; aOR indicates, adjusted odds ratio; CKD, chronic kidney disease; CRIC, Chronic Renal Insufficiency Cohort; GDF‐15, growth differentiation factor‐15; HF, heart failure; hsTnT, high‐sensitivity troponin T; KCCQ, Kansas City Cardiomyopathy Questionnaire; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; OR, odds ratio; and sST‐2, soluble suppression of tumorigenesis‐2.
P<0.01.